Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma

Xiubao Chang, Yuanxiao Zhu, Changxin Shi, A. Keith Stewart

Research output: Contribution to journalReview articlepeer-review

41 Scopus citations


Although immunomodulatory drugs (IMiDs), such as thalidomide, lenalidomide, and pomalidomide, are widely used in the treatment of multiple myeloma (MM), the molecular mechanism of IMiDs' action is largely unknown. In this review, we will summarize recent advances in the application of IMiDs in MM cancer treatment as well as their effects on immunomodulatory activities, anti-angiogenic activities, intervention of cell surface adhesion molecules between myeloma cells and bone marrow stromal cells, anti-inflammatory activities, anti-proliferation, pro-apoptotic effects, cell cycle arrest, and inhibition of cell migration and metastasis. In addition, the potential IMiDs' target protein, IMiDs' target protein's functional role, and the potential molecular mechanisms of IMiDs resistance will be discussed. We wish, by presentation of our naive discussion, that this review article will facilitate further investigation in these fields.

Original languageEnglish (US)
Pages (from-to)240-253
Number of pages14
JournalActa Biochimica et Biophysica Sinica
Issue number3
StatePublished - Mar 2014


  • E3 ubiquitin ligase
  • cancer treatment
  • cereblon
  • immunomodulatory drugs
  • multiple myeloma

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry


Dive into the research topics of 'Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma'. Together they form a unique fingerprint.

Cite this